AXQ Capital
GRCE icon

AXQ Capital’s Grace Therapeutics GRCE Stock Holding History

AXQ Capital’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.3K Buy
+12,221
New +$27.1K ﹤0.01% 990

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
JDCAI
Johnson Dunn Capital Advisors Inc Palm Harbor, Florida $140M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

AXQ Capital's GRCE Position: Q3 2026 in Review

AXQ Capital opened a new position in Grace Therapeutics (GRCE) in Q3 2026: 12,221 shares worth $26.3K. The stake represents ﹤0.01% of the portfolio and ranks #990 among its holdings.

18 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

  • AXQ Capital held 12,221 shares of Grace Therapeutics worth $26.3K as of Q3 2026.
  • Grace Therapeutics was a new AXQ Capital position in Q3 2026.
  • Grace Therapeutics made up ﹤0.01% of AXQ Capital's portfolio in Q3 2026, its #990 holding.
  • 18 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.